Biomarkers of myocardial ischemia and necrosis in 2008

Česká verzia

Authors: R. Pudil ¹; M. Tichý ²; M. Ulrychová ²; L. Horáková ¹; J. Vojáček ¹
Authors place of work: I. interní klinika Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Jan Vojáček, DrSc. ¹; Ústav klinické biochemie a diagnostiky Lékařské fakulty UK a FN Hradec Králové, přednosta prof. MUDr. Vladimír Palička, DrSc. ²
Published in the journal: Vnitř Lék 2008; 54(10): 965-970
Category: Reviews

Summary

In the review article, the authors present current knowledge of biomarkers of myocardial ischemia and necrosis. They comment new definition of myocardial infarction resulted as consensus of European Society of Cardiology and American Heart Association. They added clinically interested data about routinely used cardiomarkers (cardiac troponins and creatinkinase). At the second part, the authors focused on new biomarkers (fatty acids binding proteins, ischemia-modified albumin, glycogen phosphorylase isoenzyme BB) and its significance in diagnosis of myocardial ischemia/necrosis and their prognostic significance. Some of new promising molecules are discussed in the last part of the article.

Key words:
biomarker – myocardial necrosis and ischemia – myocardial infarction definition – troponins – creatinekinase – free fatty acid binding protein – ischemia-modified albumin – glycogenphopshorylase isoenzyme BB

Zdroje

1. Altman E, Bassand JP, Klein W et al. Myocardial infarction redefined – a consensus document of The Joint European Society of Cardiology/American College of Cardiology committee for the redefinition of myocardial infarction. The Joint European Society of Cardiology/American College of Cardiology Committee. JACC 2000; 36: 959–969.

2. Apple F, Wu A, Mair J et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndromes. Clin Chem 2005; 51: 810–825.

3. Aslan D, Apple FS. Ischemia modified albumin: clinical and analytical update. Lab Med 2004; 35: 1–5.

4. Azzazy H, Pelsers M, Christenson RH. Unbound Free Fatty Acids and Heart-Type Acid-Binding protein: Diagnostic Assays and Clinical Applications. Clin Chem 2006; 52: 19–29.

5. Bertrand ME, Simoons ML, Fox KA et al. Management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation. The Task Force on the Management of Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J 2002; 23: 1809–1840.

6. Bhagavan NV, Lai EM, Rios PA et al. Evaluation of human serum albumin cobalt binding assay for the assessment of myocardial ischemia and myocardial infarction. Clin Chem 2003; 49: 581–585.

7. Collinson P, Pulkki K, Suvisaari J et al. How well do laboratories follow guidelines on cardiac markers? The Cardiac Marker Guideline Uptake in Europe Study. Clin Chem 2008; 54: 448–449.

8. Danne O, Möckel M, Lueders C et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndromes. Am J Cardiol 2003; 91: 1060–1067.

9. Dušek J, Tichý M, Šťásek J et al. Ischemií modifikovaný albumin: nový marker myokardiální ischémie? Čas Lék Čes 2005; 144: 295–297.

10. Dušek J, Šťásek J, Tichý M et al. Prognostic significance of ischemia modified albumin after percutaneous coronary intervention. Clin Chim Acta 2006; 367: 77–80.

11. Dolci A, Panteghini M. The exciting story of cardiac biomarkers: From retrospective detection to gold standard for acute myocardial infarction and more. Clin Chim Acta 2006; 369: 179–187.

12. Engliš M. Super (ultra, high) senzitivní metody stanovení srdečních troponinů. Labor Actuell 2006; 3: 22–23.

13. Friedecký B. Troponiny – hlavní biochemické ukazatele poškození myokardu. Konfrontace mezinárodních doporučení s reálnými možnostmi klinických laboratoří. Cor Vasa 2002; 44: 422–425.

14. Friedecký B, Engliš M, Franeková J et al. Doporučení České společnosti klinické biochemie ke stanovení biochemických markerů poškození myokardu. Klin Bioch Metab 2008; 16: 50–55.

15. Glatz JF, van Bilsen M, Paulussen R et al. Release of fatty aid‑binding protein from isolated ret heart subjected to ischemia and reperfusion or the calcium paradox. Biochim Biophys Acta 1988; 961: 148–152.

16. Gomez-Munoz A, Martens JS, Steinbrecher UP. Stimulation of phospholipase D activity by oxidized LDL in mouse peritoneal macrophages. Arterioscler Thromb Vasc Biol 2000; 20: 135–143.

17. Heeschen C, Dimmeler S, Fichtlscherer S et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004; 291: 435–441.

18. Heeschen C, Fichtlscherer S, Hamm CW. Pregnancy‑associated plasma protein‑A (PAPPA) plasma level independently predict outcome in troponin negative patients with acute coronary syndrome. Circulation 2003; 108 (Suppl IV): 470.

19. Horáček JM, Pudil R, Tichý M et al. The use of biochemical markers in cardiotoxicity monitoring in patients treated for leukemia. Neoplasma 2005; 52: 430–434.

20. Horáček JM, Tichý M, Pudil R et al. New biomarkers of myocardial injury and assessment of cardiac toxicity during preparative regimen and hematopoietic cell transplantation in acute leukemia. Clin Chem Lab Med 2008; 46: 148–149.

21. Karmen A, Vroblewski F, LaDue JS. Transaminase activity in human blood. J Clin Invest 1954; 34: 126–133.

22. Khosravi J, Diamandi A, Krishna RG et al. Pregnancy associated plasma protein‑A: ultrasensitive immunoassay and determination in coronary heart disease. Clin Biochem 2002; 35: 531–538.

23. Kleinfeld AM, Kleinfeld KJ, Adams JE. Serum levels of unbound free fatty acids reveal high sensitivity for early detection of acute myocardial infarction in patient samples from the TIMI II trial. J Am Coll Cardiol 2002; 39: 312A.

24. Kleinfeld AM, Prothro D et al. Increases in serum unbound free fatty acid concentrations following coronary angioplasty. Am J Cardiol 1996; 78: 1350–1354.

25. Kurie VA, Olivek MF. Serum‑free fatty acids after acute myocardial infarction and cerebral vascular occlusion. Lancet 1966; 288: 122–127.

26. Lačnák B, Stejskal D, Jedelský L et al. Využití stanovení glykogenfosforylázy BB v diagnostice algické formy akutních koronárních syndromů. Vnitř Lék 2007; 53: 1164–1169.

27. Lund J, Qin QP, IlvaT et al. Circulating pregnancy associated plasma protein A predicts outcome in patients with acute coronary syndrome but no troponin I elevation. Circulation 2003; 108: 1924–1926.

28. Panteghini M, Gerhardt W, Apple FS et al. Quality specifications for cardiac troponin assays. Clin Chem Lab Med 2001; 39: 175–179.

29. Pudil R, Horáček J. Je kardiotoxicita problémem onkologa nebo také kardiologa? Vnitř Lék 2006; 52: 306–307.

30. Pudil R, Horáček J, Horáčková J et al. Anthracycline therapy can induce very early increase in QT dispersion and QT(c) prolongation. Leuk Res 2008; 32: 998–999.

31. Pudil R, Pařízek P, Tichý M et al. Detekce poškození myokardu při radiofrekvenčních ablacích s využitím ně-kte-rých nových kardiomarkerů. Cor Vasa 2008; v tisku.

32. Stejskal D, Lačňák B, Juráková R et al. První zkušenosti se stanovením vazebné kapacity pro kobalt (ACB) v diagnostice akutního koronárního syndromu (pilotní studie). Vnitř Lék 2004; 50: 734–739.

33. Tichý M, Gregor J. Přehled biochemických markerů poškození myokardu. Klin Biochem Metab 2002; 10: 176–179.

34. Thygesen K, Albert JS, White HD et al. Universal definition of myocardial infarction. Eur Heart Journal 2007; 28: 2525–2538.

35. Van de Werf F, Ardissino D, Betriu A et al. Management of acute myocardial infarction inpatients presenting with ST‑segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24: 28–66.